Lilly
1Q Revenues: $4.2 billion (+14%)
1Q Earnings: $508.7 million (-39%)
Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve, collectively grew 57% to $1.3 billion, and accounted for 30% of total sales, compared with 22% of in 1Q2006. Earnings for the quarter were affected by in-process R&D charges associated with the ICOS acquisition and OSI in-licensing agreement and restructuring charges associated with "manufacturing decisions"; Lilly recently decided to close some European locations and halt construction of a plant in Virginia.
Magazine
